Modifiable risk factors for kidney cancer

A healthy lifestyle can make a direct, positive and beneficial change to one’s life. As such, four new studies proving that diet, exercise and maintaining a healthy weight helps to improve your urologic health, were presented during a special press conference at the 111th Annual Scientific Meeting of the American Urological Association (AUA) held in […]

read more

Immunotherapy before and after surgery for kidney cancer

At the American Urological Association’s Annual Meeting in San Diego this week, Dr Harshman spoke about treating renal cell carcinoma (RCC) before and after surgery with immunotherapy. Although results from the EVEREST trial and others are eagerly anticipated, there has been no major success using adjuvant therapies (treatment after surgery) in kidney cancer to date. […]

read more

Common supplement boosts kidney cancer therapy

A recent study published in the journal Molecular Cancer Therapeutics by researchers at University College Davis Comprehensive Cancer Center in the US, shows that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces the invasiveness of renal cell carcinomas (RCC), growth rate, and blood vessel growth when combined with […]

read more

Vaccines for renal cell carcinoma

This OncLive panel discussion focuses on the treatment of renal cell carcinoma (RCC) with vaccines, specifically the results from the ADAPT trial, and suggest that the way forward for vaccine treatment is in combination with other RCC drugs. They then move on to talk about combination trials with immunotherapy and TKI drugs; however, combinations of […]

read more

Cabozantinib receives FDA approval for kidney cancer

Exelixis has announced that the US Food and Drug Administration (FDA) has approved CABOMETYX™ (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate clinically meaningful improvement […]

read more

Link between obesity and kidney cancer identified

A study by researchers at The University of Texas MD Anderson Cancer Centre has shown that receptors for the hormone, leptin, may be associated with tumour recurrence in patients with renal cell carcinoma (RCC). This study provides further understanding about the molecular links between obesity and RCC tumour formation and prognosis. The findings are being […]

read more

Novel therapies shaking up the treatment of kidney cancer

The following round table discussion between a panel of doctors (oncologists) discusses the recent advances in how renal cell carcinoma (RCC) is treated. Although treatment options for RCC have improved dramatically over the past decade, oncologists often face difficult decisions in selecting the right course of treatment for the individual patient, such as; which drug(s) […]

read more

EU approves nivolumab for renal cell carcinoma (RCC)

Nivolumab (Opdivo) has received approval for 2 new indications from the European Commission. Nivolumab is an programmed death receptor-1 (PD-1) immune checkpoint inhibitor that activates the immune system’s T cells to detect and attack cancer cells. The drug is already approved in Europe for use in previously treated patients with metastatic squamous non-small-cell lung cancer […]

read more

Christy Watson talks about renal cancer

Christy talks about her experience and why she’s hosting her 3rd Green Ribbon Ball – she’s raised more than £75,000 for the charity. Get in touch at Renal Cancer Research Fund, Scotland. During the interview, Christy talks about her experience of being on a kidney cancer clinical trial, symptoms of kidney cancer, and the reason for starting […]

read more
Showing 821 to 829 of 829 results
  TOP